• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.

作者信息

Yano Akihiro, Kagawa Makoto, Takeshita Hideki, Okada Yohei, Morozumi Makoto, Kawakami Satoru

机构信息

Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.

出版信息

Int J Urol. 2017 Dec;24(12):861-862. doi: 10.1111/iju.13445. Epub 2017 Sep 11.

DOI:10.1111/iju.13445
PMID:28895205
Abstract
摘要

相似文献

1
Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.基线低血清硫酸脱氢表雄酮可预测激素初治的前列腺癌骨转移患者对激素治疗的反应不佳。
Int J Urol. 2017 Dec;24(12):861-862. doi: 10.1111/iju.13445. Epub 2017 Sep 11.
2
Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Ann Acad Med Singap. 2010 Jul;39(7):580-2.
3
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.比卡鲁胺 150mg 挽救性治疗去势抵抗性前列腺癌。
Urology. 2010 Nov;76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. Epub 2010 Mar 29.
4
Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.对日本前列腺癌联合雄激素阻断（包括比卡鲁胺）风险评估的编辑评论：临床应用与验证
Int J Urol. 2013 Jul;20(7):714-5. doi: 10.1111/iju.12044. Epub 2012 Dec 6.
5
[Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].[激素治疗后前列腺腺癌脉络膜转移灶的消退]
Arch Soc Esp Oftalmol. 2007 Nov;82(11):715-7.
6
Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
Anticancer Res. 2001 Jan-Feb;21(1B):551-6.
7
Sense and Sensibility.
Am J Med. 2021 Dec;134(12):1570-1571. doi: 10.1016/j.amjmed.2021.05.014. Epub 2021 Jun 30.
8
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.日本前列腺癌风险评估：联合雄激素阻断治疗包括比卡鲁胺的临床应用和验证。
Int J Urol. 2013 Jul;20(7):708-14. doi: 10.1111/iju.12037. Epub 2012 Dec 6.
9
A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.雄激素拮抗剂撤药反应显著：病例报告及文献复习。
J Hematol Oncol. 2008 Nov 5;1:21. doi: 10.1186/1756-8722-1-21.
10
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).根治性治疗（局部手术后放疗与雄激素剥夺联合治疗）
Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-71. doi: 10.1016/j.clon.2007.01.001. Epub 2007 Feb 7.

引用本文的文献

1
A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.血清脱氢表雄酮浓度高是血清前列腺特异性抗原<10ng/ml 的男性候选主动监测的预测因子。
BMC Cancer. 2022 Nov 12;22(1):1169. doi: 10.1186/s12885-022-10251-w.
2
Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.骨骼微环境中前列腺癌的代谢谱分析确定葡萄糖-6-磷酸脱氢酶（G6PD）是生长和存活的关键调节因子。
Sci Adv. 2022 Feb 25;8(8):eabf9096. doi: 10.1126/sciadv.abf9096.
3
Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer.
硫酸脱氢表雄酮的初始3个月动态变化可预测转移性前列腺癌患者对初始雄激素剥夺治疗的反应性。
Asian J Androl. 2019 Nov-Dec;21(6):635-636. doi: 10.4103/aja.aja_9_19.